Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Innovation Action · Running

HYDROHEAL Multi-functional hydrogels for promoting bone fracture healing through local induced release of pharmaceutical agents and gradual matrix replacement by the regenerating bone

Coordinator
Universitat Politecnica De Valencia, Spain
Runs
1 June 2025 to 31 May 2029
Status
Running
EU funding
€6.5m
Total cost
—
Partners
13 organisations in 7 countries
Type
Innovation Action
Grant agreement
101178398

What the project is doing

In the project's own words, from its summary on CORDIS.

Bone atrophy and fractures, resulting from trauma, infections, osteoporosis, or cancer, are global health concerns. Standard care with cement and bone grafts has limitations. Synthetic polymers like polymethyl methacrylate risk leakage, spinal issues, and poor healing. Donor shortages for allogenic bone grafting and invasive procedures pose risks such as rejection and viral transmission. HYDROHEAL innovates with hydrogel formulations to address bone strength challenges by treating vertebral and alveolar fractures.

HYDROHEAL aims to develop safe, sustainable scaling, and cost-effective formulations using renewable biomaterials for targeted drug delivery, aligning closely with the EU Circular Economy Action Plan and Chemicals Strategy for Sustainability. It is ready to introduce a new era in fracture therapy. The proposed self-solidifying hydrogels release active pharmaceutical ingredients locally upon external stimulation, potentially improving treatment efficacy, preventing infections, and speeding up fracture healing.

The objectives of the project are:1. Develop novel injectable hydrogel formulations combining natural substance derivates to enhance healing, inhibit bacterial growth, and monitor therapy progress in vivo.2. Simultaneously manufacture carriers as micro- and nano-particles, surface-functionalized to incorporate pharmaceutical agents, releaseable upon external stimuli for tailored drug release.3. Validate safe and optimized hydrogel formulations for treating vertebral and alveolar bone fractures through in vitro and in vivo tests.4.

Demonstrate scalable and sustainable biomaterial manufacturing through safe design methods, machine learning, and predictive life cycle assessment.5. Develop machine learning and hybrid digital modeling methods, combining adaptive design of experiments and physics-based modeling with advanced characterization techniques.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Politecnica De ValenciaValenciaSpainCoordinator
Vet Ex Machina LimitedNicosiaCyprusParticipant
Consultech Technologieberatung GmbHBerlinGermanyParticipant
Asphalion SLBarcelonaSpainParticipant
Sitec Pharmabio SLEsplugues De LlobregatSpainParticipant
Universitat Politecnica De CatalunyaBarcelonaSpainParticipant
Royal College of Surgeons in IrelandDublin 2IrelandParticipant
Politecnico Di TorinoTorinoItalyParticipant
Separeco SrlMacelloItalyParticipant
Fluidinova SAMaiaPortugalParticipant
Centre for Process Innovation Limited LbgRedcar ClevelandUnited KingdomParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomParticipant
University of WarwickCoventryUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI